NASDAQ:PCRX - Pacira BioSciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $77.50
  • Forecasted Upside: 22.88 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$63.07
▼ -3.27 (-4.93%)
1 month | 3 months | 12 months
Get New Pacira BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$77.50
▲ +22.88% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $77.50, with a high forecast of $94.00 and a low forecast of $48.00. The average price target represents a 22.88% upside from the last price of $63.07.
Buy
The current consensus among 12 contributing investment analysts is to buy stock in Pacira BioSciences. This rating has held steady since November 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 1 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/15/2021Berenberg BankInitiated CoverageBuy$93.00High
i
4/9/2021Berenberg BankInitiated CoverageBuy$93.00Low
i
3/8/2021HC WainwrightBoost Price TargetBuy$70.00 ➝ $86.00Medium
i
3/1/2021HC WainwrightBoost Price TargetBuy$70.00 ➝ $86.00Low
i
2/26/2021BarclaysBoost Price TargetOverweight$79.00 ➝ $94.00Medium
i
2/11/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$72.00 ➝ $75.00Low
i
1/25/2021Northland SecuritiesBoost Price TargetOutperform$67.00 ➝ $72.00Medium
i
1/21/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$63.00 ➝ $75.00High
i
Rating by A. Fadia at SVB Leerink LLC
1/20/2021Piper SandlerBoost Price TargetOverweight$65.00 ➝ $90.00Low
i
1/8/2021Needham & Company LLCBoost Price TargetBuy$67.00 ➝ $76.00High
i
1/6/2021Royal Bank of CanadaBoost Price TargetOutperform$65.00 ➝ $70.00N/A
i
12/14/2020BarclaysBoost Price TargetOverweight$73.00 ➝ $79.00Low
i
12/9/2020Needham & Company LLCLower Price TargetBuy$68.00 ➝ $67.00High
i
11/2/2020WedbushLower Price TargetOutperform$85.00 ➝ $83.00Low
i
Rating by Liana Moussatos at Wedbush
10/7/2020WedbushReiterated RatingBuy$85.00Medium
i
Rating by Liana Moussatos at Wedbush
9/30/2020Jefferies Financial GroupBoost Price Target$69.00 ➝ $75.00Low
i
9/21/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$58.00 ➝ $67.00Medium
i
9/9/2020Needham & Company LLCBoost Price TargetBuy$64.00 ➝ $68.00High
i
8/17/2020WedbushReiterated RatingBuy$85.00Medium
i
Rating by Liana Moussatos at Wedbush
8/14/2020TruistBoost Price Target$54.00 ➝ $65.00Low
i
8/10/2020HC WainwrightBoost Price TargetBuy$68.00 ➝ $70.00High
i
Rating by Oren Livnat at HC Wainwright
7/20/2020WedbushReiterated RatingBuy$85.00Low
i
Rating by Liana Moussatos at Wedbush
7/13/2020HC WainwrightReiterated RatingBuy$63.00 ➝ $68.00High
i
7/10/2020Jefferies Financial GroupBoost Price TargetBuy$53.00 ➝ $69.00Low
i
7/6/2020Needham & Company LLCBoost Price TargetBuy$52.00 ➝ $64.00Medium
i
7/6/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$49.00 ➝ $65.00Medium
i
Rating by David Amsellem at Piper Sandler
7/2/2020WedbushReiterated RatingBuy$85.00N/A
i
Rating by Liana Moussatos at Wedbush
7/1/2020Royal Bank of CanadaBoost Price TargetOutperform$56.00 ➝ $62.00High
i
6/30/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $58.00Medium
i
Rating by A. Fadia at SVB Leerink LLC
6/30/2020Northland SecuritiesBoost Price TargetMarket Perform$50.00 ➝ $54.00Low
i
5/27/2020Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
i
5/26/2020GuggenheimInitiated CoverageNeutralLow
i
5/13/2020Royal Bank of CanadaReiterated RatingBuy$56.00High
i
5/12/2020WedbushReiterated RatingBuy$85.00High
i
Rating by Liana Moussatos at Wedbush
5/8/2020SVB LeerinkBoost Price TargetBuy$44.00 ➝ $45.00Medium
i
Rating by A. Fadia at SVB Leerink LLC
5/7/2020Stifel NicolausLower Price TargetHold$49.00 ➝ $48.00Low
i
Rating by Derek Archila at Stifel Nicolaus
4/30/2020Needham & Company LLCLower Price TargetBuy$56.00 ➝ $52.00High
i
4/27/2020WedbushReiterated RatingBuy$85.00Medium
i
Rating by Liana Moussatos at Wedbush
4/17/2020Northland SecuritiesReiterated RatingBuy$50.00High
i
4/7/2020Northland SecuritiesInitiated CoverageOutperform$50.00High
i
3/23/2020Piper SandlerLower Price Target$60.00 ➝ $49.00High
i
Rating by David Amsellem at Piper Sandler
3/23/2020Royal Bank of CanadaLower Price TargetOutperform$65.00 ➝ $56.00High
i
3/20/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$46.00 ➝ $44.00High
i
Rating by A. Fadia at SVB Leerink LLC
2/24/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $63.00Medium
i
2/20/2020WedbushReiterated RatingBuy$85.00N/A
i
Rating by Liana Moussatos at Wedbush
2/20/2020Stifel NicolausReiterated RatingHold$49.00High
i
2/20/2020Piper SandlerBoost Price TargetBuy$54.00 ➝ $60.00Low
i
1/23/2020SunTrust BanksInitiated CoverageBuy$60.00Low
i
1/7/2020WedbushReiterated RatingBuy$85.00Low
i
Rating by Liana Moussatos at Wedbush
12/18/2019Royal Bank of CanadaReiterated RatingBuyLow
i
12/17/2019WedbushReiterated RatingBuy$85.00Medium
i
Rating by Liana Moussatos at Wedbush
11/8/2019BarclaysBoost Price TargetOverweight$52.00 ➝ $55.00Medium
i
Rating by Balaji Prasad at Barclays PLC
11/7/2019Needham & Company LLCReiterated RatingBuy$56.00High
i
11/7/2019CowenReiterated RatingHold$41.00High
i
11/6/2019BTIG ResearchInitiated CoverageBuy$56.00 ➝ $56.00Medium
i
10/8/2019Jefferies Financial GroupSet Price TargetBuy$60.00Low
i
Rating by David Steinberg at Jefferies Financial Group Inc.
8/9/2019Stifel NicolausSet Price TargetHold$42.00Low
i
Rating by Derek Archila at Stifel Nicolaus
8/9/2019BMO Capital MarketsLower Price TargetMarket Perform$46.00 ➝ $43.00Low
i
Rating by Gary Nachman at BMO Capital Markets
6/28/2019WedbushSet Price TargetBuy$85.00Medium
i
Rating by Liana Moussatos at Wedbush
6/12/2019WedbushReiterated RatingOutperform$85.00Low
i
Rating by Liana Moussatos at Wedbush
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$52.00Low
i
5/6/2019MizuhoUpgradeUnderperform ➝ Neutral$29.00 ➝ $38.00Low
i
5/3/2019BMO Capital MarketsSet Price TargetHold$46.00Low
i
Rating by Gary Nachman at BMO Capital Markets
5/2/2019Stifel NicolausUpgradeSell ➝ Hold$45.00Low
i
Rating by Derek Archila at Stifel Nicolaus
4/9/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
3/8/2019WedbushReiterated RatingOutperform$85.00Low
i
Rating by Liana Moussatos at Wedbush
3/8/2019Stifel NicolausReiterated RatingPositive ➝ Sell$33.00Low
i
3/1/2019BMO Capital MarketsSet Price TargetHold$44.00Medium
i
Rating by Gary Nachman at BMO Capital Markets
3/1/2019CowenReiterated RatingHoldLow
i
2/12/2019National SecuritiesInitiated CoverageSellMedium
i
2/1/2019MizuhoDowngradeNeutral ➝ UnderperformHigh
i
1/29/2019WedbushSet Price TargetBuy$91.00High
i
Rating by Liana Moussatos at Wedbush
11/5/2018WedbushSet Price TargetBuy$85.00 ➝ $90.00Low
i
Rating by Liana Moussatos at Wedbush
11/5/2018MizuhoBoost Price TargetNeutral$46.00Medium
i
11/2/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$45.00 ➝ $50.00Low
i
11/2/2018Jefferies Financial GroupBoost Price TargetBuy$60.00Low
i
11/2/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$40.00 ➝ $47.00Low
i
11/2/2018Royal Bank of CanadaSet Price TargetBuy$60.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
11/2/2018HC WainwrightBoost Price TargetBuy$60.00High
i
Rating by Oren Livnat at HC Wainwright
11/1/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Buy$56.00 ➝ $63.00High
i
Rating by Donald Ellis at JMP Securities
11/1/2018Needham & Company LLCSet Price TargetBuy$60.00High
i
Rating by Serge Belanger at Needham & Company LLC
11/1/2018Piper Jaffray CompaniesSet Price TargetBuy$55.00High
i
Rating by David Amsellem at Piper Jaffray Companies
11/1/2018MizuhoReiterated RatingHold$43.00High
i
10/10/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $48.00High
i
10/9/2018Piper Jaffray CompaniesReiterated RatingBuy$51.00High
i
Rating by David Amsellem at Piper Jaffray Companies
10/2/2018Canaccord GenuitySet Price TargetHold ➝ Hold$45.00 ➝ $49.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
9/19/2018Royal Bank of CanadaSet Price TargetBuy$55.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
9/13/2018Stifel NicolausInitiated CoverageSell$41.00Low
i
9/4/2018Canaccord GenuitySet Price TargetHold$45.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
8/17/2018Canaccord GenuityReiterated RatingHold$45.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
8/6/2018BarclaysBoost Price TargetOverweight ➝ Buy$40.00 ➝ $50.00Low
i
Rating by Douglas Tsao at Barclays PLC
8/6/2018WedbushReiterated RatingOutperform$85.00 ➝ $80.00Low
i
Rating by Liana Moussatos at Wedbush
8/6/2018WedbushSet Price TargetOutperform ➝ Outperform$85.00Low
i
Rating by Liana Moussatos at Wedbush
8/6/2018Bank of AmericaDowngradeBuy ➝ NeutralLow
i
8/3/2018Needham & Company LLCUpgradeHold ➝ Buy$54.00High
i
Rating by Serge Belanger at Needham & Company LLC
8/3/2018HC WainwrightReiterated RatingBuy$52.00High
i
Rating by Oren Livnat at HC Wainwright
8/2/2018Piper Jaffray CompaniesSet Price TargetBuy$48.00High
i
Rating by David Amsellem at Piper Jaffray Companies
8/2/2018Royal Bank of CanadaSet Price TargetBuy$50.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
8/2/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Neutral$40.00High
i
7/30/2018Canaccord GenuityReiterated RatingHold$34.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
7/26/2018HC WainwrightSet Price TargetBuy$48.00High
i
Rating by Oren Livnat at HC Wainwright
7/10/2018CowenReiterated RatingHoldMedium
i
7/10/2018HC WainwrightReiterated RatingBuy$48.00Medium
i
Rating by Oren Livnat at HC Wainwright
6/29/2018Canaccord GenuitySet Price TargetHold$34.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
6/29/2018MizuhoReiterated RatingHold$31.00Low
i
5/30/2018Canaccord GenuitySet Price TargetHold$34.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
5/17/2018OppenheimerReiterated RatingHoldLow
i
Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/11/2018Canaccord GenuitySet Price TargetHold$34.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
5/4/2018JMP SecuritiesSet Price TargetOutperform ➝ Buy$65.00 ➝ $56.00Medium
i
5/3/2018Canaccord GenuitySet Price TargetHold$34.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
5/3/2018MizuhoReiterated RatingHold$31.00Medium
i
5/3/2018HC WainwrightSet Price TargetBuy$48.00Low
i
Rating by Oren Livnat at HC Wainwright
4/30/2018WedbushReiterated RatingOutperform$80.00Medium
i
4/10/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$40.00 ➝ $43.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
4/9/2018WedbushLower Price TargetOutperform$72.00 ➝ $80.00High
i
4/9/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$31.00 ➝ $34.00Low
i
4/9/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Hold$40.00 ➝ $43.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
4/9/2018HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $48.00Medium
i
Rating by Oren Livnat at HC Wainwright
4/9/2018Piper Jaffray CompaniesSet Price TargetBuy$44.00Medium
i
Rating by David Amsellem at Piper Jaffray Companies
4/9/2018Canaccord GenuityBoost Price TargetHold ➝ Hold$32.00 ➝ $34.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
4/8/2018Seaport Global SecuritiesSet Price TargetBuy$48.00Medium
i
Rating by Corey Davis at Seaport Global Securities
3/21/2018MizuhoLower Price TargetNeutral ➝ Neutral$44.00 ➝ $31.00High
i
3/20/2018Seaport Global SecuritiesReiterated RatingPositive ➝ Buy$42.00Medium
i
3/1/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$32.00 ➝ $31.00Medium
i
3/1/2018Royal Bank of CanadaSet Price TargetBuy$44.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
3/1/2018HC WainwrightSet Price TargetBuy$45.00High
i
Rating by Oren Livnat at HC Wainwright
3/1/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
2/16/2018Needham & Company LLCDowngradeBuy ➝ Hold$55.00High
i
Rating by Serge Belanger at Needham & Company LLC
2/16/2018BarclaysReiterated RatingBuy$40.00High
i
2/16/2018Canaccord GenuityReiterated RatingHold$32.00High
i
Rating by Dewey Steadman at Canaccord Genuity
2/15/2018BMO Capital MarketsLower Price TargetMarket Perform$41.00 ➝ $32.00High
i
2/15/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Derek Archila at Oppenheimer Holdings Inc.
2/13/2018Piper Jaffray CompaniesSet Price TargetBuy$49.00Low
i
Rating by David Amsellem at Piper Jaffray Companies
1/30/2018Canaccord GenuityLower Price TargetHold ➝ Hold$46.00 ➝ $42.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
1/19/2018Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$50.00Low
i
1/5/2018WedbushReiterated RatingBuyLow
i
1/4/2018HC WainwrightSet Price TargetBuy ➝ Buy$52.00 ➝ $55.00Low
i
Rating by Oren Livnat at HC Wainwright
1/4/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Chris Schott at JPMorgan Chase & Co.
1/4/2018Canaccord GenuitySet Price TargetBuy ➝ Buy$42.00 ➝ $46.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
1/4/2018Royal Bank of CanadaSet Price TargetBuy$54.00High
i
Rating by Randall Stanicky at Royal Bank of Canada
1/2/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$46.00Low
i
Rating by A. Fadia at SVB Leerink LLC
12/29/2017Canaccord GenuitySet Price TargetHold$42.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
12/20/2017WedbushReiterated RatingBuy$80.00Low
i
12/18/2017JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$47.00High
i
Rating by Chris Schott at JPMorgan Chase & Co.
11/29/2017Canaccord GenuitySet Price TargetHold$42.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
11/29/2017MizuhoDowngradeBuy ➝ Neutral$53.00 ➝ $44.00Medium
i
11/20/2017WedbushReiterated RatingBuy$80.00N/A
i
11/16/2017Janney Montgomery ScottSet Price TargetSell$27.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
11/9/2017Canaccord GenuityBoost Price TargetHold$33.00 ➝ $38.00N/A
i
Rating by Dewey Steadman at Canaccord Genuity
11/9/2017OppenheimerReiterated RatingHoldN/A
i
11/9/2017HC WainwrightReiterated RatingBuy ➝ Buy$52.00N/A
i
Rating by Corey Davis at HC Wainwright
11/9/2017Jefferies Financial GroupLower Price TargetBuy$52.00N/A
i
11/8/2017BMO Capital MarketsBoost Price TargetMarket Perform$38.00 ➝ $39.00N/A
i
10/30/2017Canaccord GenuityDowngradeBuy ➝ Hold$44.00 ➝ $33.00N/A
i
Rating by Dewey Steadman at Canaccord Genuity
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$55.00N/A
i
10/26/2017Janney Montgomery ScottDowngradeNeutral ➝ Sell$27.00N/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
10/25/2017WedbushReiterated RatingOutperform$87.00N/A
i
10/19/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$55.00 ➝ $52.00N/A
i
Rating by Serge Belanger at Needham & Company LLC
10/13/2017Royal Bank of CanadaReiterated RatingBuy$54.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
10/4/2017Bank of AmericaLower Price TargetBuy$46.00 ➝ $45.00Low
i
10/1/2017Canaccord GenuityReiterated RatingBuy$48.00 ➝ $44.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
9/28/2017The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$41.00Medium
i
9/26/2017Needham & Company LLCReiterated RatingBuyLow
i
Rating by Serge Belanger at Needham & Company LLC
9/25/2017MizuhoReiterated RatingBuy$53.00Medium
i
9/7/2017Jefferies Financial GroupReiterated RatingBuy$59.00Medium
i
Rating by David Steinberg at Jefferies Financial Group Inc.
9/7/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLow
i
9/7/2017OppenheimerInitiated CoverageMarket PerformMedium
i
9/6/2017UBS GroupInitiated CoverageMarket PerformMedium
i
9/5/2017Royal Bank of CanadaReiterated RatingOutperform$54.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
8/29/2017Canaccord GenuityLower Price TargetBuy$56.00 ➝ $48.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
8/23/2017WedbushReiterated RatingOutperform$87.00Medium
i
8/22/2017MizuhoReiterated RatingBuy$54.00 ➝ $53.00Low
i
8/22/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$55.00Low
i
8/21/2017Janney Montgomery ScottUpgradeSell ➝ Neutral$31.00Low
i
Rating by Ken Trbovich at Janney Montgomery Scott
8/3/2017BMO Capital MarketsLower Price TargetMarket Perform$42.00 ➝ $40.00Low
i
8/3/2017HC WainwrightSet Price TargetBuy$59.00Medium
i
Rating by Corey Davis at HC Wainwright
8/2/2017CowenReiterated RatingHoldMedium
i
Rating by Boris Peaker at Cowen Inc
7/31/2017Canaccord GenuityReiterated RatingBuy$56.00Low
i
Rating by Dewey Steadman at Canaccord Genuity
7/30/2017Royal Bank of CanadaSet Price TargetBuy$58.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
7/26/2017MizuhoReiterated RatingBuy$54.00Medium
i
7/25/2017Canaccord GenuitySet Price TargetBuy$56.00High
i
Rating by Dewey Steadman at Canaccord Genuity
7/19/2017WedbushReiterated RatingOutperform$87.00Low
i
7/14/2017CowenReiterated RatingHoldLow
i
Rating by Boris Peaker at Cowen Inc
6/27/2017Royal Bank of CanadaSet Price TargetBuy$58.00N/A
i
Rating by Randall Stanicky at Royal Bank of Canada
6/21/2017WedbushReiterated RatingOutperform$87.00High
i
5/24/2017WedbushReiterated RatingOutperform$87.00Low
i
5/22/2017Canaccord GenuitySet Price TargetBuy$60.00Medium
i
Rating by Dewey Steadman at Canaccord Genuity
5/15/2017Royal Bank of CanadaSet Price TargetBuy$58.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
5/15/2017Canaccord GenuityReiterated RatingBuy$60.00Low
i
5/6/2017HC WainwrightSet Price TargetBuy$59.00Low
i
Rating by Corey Davis at HC Wainwright
5/5/2017Canaccord GenuityReiterated RatingBuy$60.00Low
i
5/5/2017MizuhoLower Price TargetBuy ➝ Buy$57.00 ➝ $54.00Medium
i
4/19/2017WedbushReiterated RatingOutperform$89.00Medium
i
4/13/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$58.00Medium
i
4/4/2017Jefferies Financial GroupSet Price TargetBuy$60.00Medium
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/29/2017Canaccord GenuityReiterated RatingBuy$60.00Low
i
3/23/2017MizuhoLower Price TargetBuy$59.00 ➝ $54.00High
i
3/22/2017WedbushReiterated RatingOutperform ➝ Outperform$21.00 ➝ $89.00High
i
3/21/2017BarclaysReiterated RatingOverweight ➝ Overweight$54.00 ➝ $59.00High
i
3/20/2017SVB LeerinkReiterated RatingMarket PerformHigh
i
3/16/2017HC WainwrightSet Price TargetBuy$59.00High
i
Rating by Corey Davis at HC Wainwright
3/14/2017Piper Jaffray CompaniesReiterated RatingOverweight$60.00Medium
i
3/3/2017MizuhoBoost Price TargetBuy$59.00N/A
i
3/2/2017Jefferies Financial GroupSet Price TargetBuy$60.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
3/2/2017CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
3/2/2017Janney Montgomery ScottDowngradeNeutral ➝ Sell$38.00N/A
i
3/2/2017HC WainwrightBoost Price TargetBuy ➝ Buy$48.00 ➝ $59.00N/A
i
Rating by Corey Davis at HC Wainwright
3/2/2017WedbushReiterated RatingOutperform$89.00N/A
i
3/2/2017BMO Capital MarketsReiterated RatingHold$45.00N/A
i
2/22/2017WedbushReiterated RatingOutperformN/A
i
2/21/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$55.00N/A
i
2/8/2017WedbushReiterated RatingOutperform$89.00N/A
i
2/2/2017Jefferies Financial GroupSet Price TargetBuy$53.00N/A
i
Rating by David Steinberg at Jefferies Financial Group Inc.
1/28/2017MizuhoReiterated RatingBuy$41.00 ➝ $50.00N/A
i
1/25/2017WedbushReiterated RatingOutperform$89.00N/A
i
1/25/2017CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
1/25/2017HC WainwrightSet Price TargetBuy$46.00 ➝ $48.00N/A
i
Rating by Corey Davis at HC Wainwright
1/10/2017BMO Capital MarketsReiterated RatingMarket Perform$35.00N/A
i
1/9/2017MizuhoReiterated RatingBuy$41.00N/A
i
1/5/2017WedbushReiterated RatingOutperform$89.00N/A
i
1/3/2017HC WainwrightInitiated CoverageBuy$43.00N/A
i
12/30/2016Janney Montgomery ScottBoost Price TargetNeutral$31.00 ➝ $34.00N/A
i
12/21/2016WedbushReiterated RatingOutperform$89.00N/A
i
12/21/2016MizuhoLower Price TargetBuy$46.00 ➝ $41.00N/A
i
12/7/2016Jefferies Financial GroupReiterated RatingBuy$53.00N/A
i
12/2/2016Janney Montgomery ScottInitiated CoverageNeutral$31.00N/A
i
12/1/2016The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$36.00N/A
i
11/26/2016BMO Capital MarketsReiterated RatingMarket Perform$35.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
11/26/2016MizuhoReiterated RatingBuy$46.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
11/6/2016WedbushReiterated RatingOutperform$93.00 ➝ $89.00N/A
i
11/3/2016BMO Capital MarketsReiterated RatingHold$35.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
11/3/2016MizuhoLower Price TargetBuy$64.00 ➝ $46.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
10/27/2016BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$36.00 ➝ $35.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
10/19/2016WedbushLower Price TargetOutperform$109.00 ➝ $93.00N/A
i
10/14/2016CowenReiterated RatingHoldN/A
i
10/7/2016Brean CapitalInitiated CoverageHoldN/A
i
Rating by jonathan aschoff at Brean Capital
9/27/2016WedbushReiterated RatingOutperform$109.00N/A
i
Rating by Liana Moussatos at Wedbush
9/26/2016Jefferies Financial GroupReiterated RatingBuy$74.00 ➝ $60.00N/A
i
9/21/2016WedbushReiterated RatingOutperform$109.00N/A
i
Rating by Liana Moussatos at Wedbush
9/20/2016CowenReiterated RatingHoldN/A
i
9/7/2016CowenInitiated CoverageMarket PerformN/A
i
8/5/2016BMO Capital MarketsReiterated RatingSell$36.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
8/5/2016Brean CapitalReiterated RatingHoldN/A
i
Rating by Jonathan Aschoff at Brean Capital
8/4/2016WedbushReiterated RatingOutperform$109.00 ➝ $105.00N/A
i
Rating by Liana Moussatos at Wedbush
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$81.00N/A
i
8/2/2016MizuhoReiterated RatingBuy$64.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/28/2016BMO Capital MarketsReiterated RatingSellN/A
i
Rating by Gary Nachman at BMO Capital Markets
7/20/2016MizuhoReiterated RatingBuy$64.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/20/2016WedbushReiterated RatingOutperform$105.00N/A
i
7/19/2016BMO Capital MarketsReiterated RatingSell$36.00N/A
i
Rating by Gary Nachman at BMO Capital Markets
7/1/2016MizuhoReiterated RatingOutperform$64.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
7/1/2016Brean CapitalDowngradeBuy ➝ HoldN/A
i
Rating by Jonathan Aschoff at Brean Capital
6/28/2016BMO Capital MarketsInitiated CoverageUnderperform$36.00N/A
i
6/22/2016MizuhoReiterated RatingBuyN/A
i
Rating by Irina Rivkind Koffler at Mizuho
6/22/2016WedbushReiterated RatingOutperform$105.00N/A
i
Rating by Liana Moussatos at Wedbush
5/26/2016MizuhoReiterated RatingBuyN/A
i
Rating by Irina Rivkind Koffler at Mizuho
5/25/2016WedbushLower Price TargetOutperform$113.00 ➝ $105.00N/A
i
Rating by Liana Moussatos at Wedbush
5/4/2016WedbushReiterated RatingOutperform$113.00N/A
i
Rating by Liana Moussatos at Wedbush
5/3/2016MizuhoLower Price TargetBuy$71.00 ➝ $64.00N/A
i
Rating by Irina Rivkind Koffler at Mizuho
4/20/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Corey Davis at Canaccord Genuity
4/20/2016WedbushReiterated RatingOutperform$113.00N/A
i
Rating by Liana Moussatos at Wedbush
4/19/2016MizuhoInitiated CoverageBuy$79.00N/A
i
(Data available from 4/18/2016 forward)
Pacira BioSciences logo
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $63.07
$60.72
$64.88

50 Day Range

MA: $70.38
$66.34
$74.45

52 Week Range

Now: $63.07
$33.47
$80.00

Volume

1,008,258 shs

Average Volume

488,850 shs

Market Capitalization

$2.77 billion

P/E Ratio

22.21

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, Berenberg Bank, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, Northland Securities, Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for PCRX.

What is the current price target for Pacira BioSciences?

12 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $77.50, suggesting a possible upside of 22.9%. Barclays PLC has the highest price target set, predicting PCRX will reach $94.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $48.00 for Pacira BioSciences in the next year.
View the latest price targets for PCRX.

What is the current consensus analyst rating for Pacira BioSciences?

Pacira BioSciences currently has 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PCRX will outperform the market and that investors should add to their positions of Pacira BioSciences.
View the latest ratings for PCRX.

What other companies compete with Pacira BioSciences?

How do I contact Pacira BioSciences' investor relations team?

Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is 973-254-3560 and its investor relations email address is [email protected] The official website for Pacira BioSciences is www.pacira.com.